Literature DB >> 18161670

High blood flow rates with adjustment of needle diameter do not increase hemolysis during hemodialysis treatment.

F Techert1, S Techert, L Woo, W Beck, H Lebsanft, V Wizemann.   

Abstract

BACKGROUND: Higher blood flow in dialysis therapy is often avoided due to concerns about shear-induced blood damage despite the lack of reliable data.
OBJECTIVE: This study investigated the influence of higher blood flow rates on plasma free hemoglobin (Hb) concentration after hemodialysis (HD) treatment.
METHODS: Thirty-two chronic HD patients were treated once with a blood flow rate of 250 mL/min using a 17G needle, and once with a blood flow rate of 500 mL/min using a 14G needle. Arterial and venous pressure and blood pressure (BP) were recorded before and after treatment. Blood samples were taken before and after treatment for analysis of plasma free Hb, pH, HCO3, base excess, hematocrit value, urea, sodium, potassium and calcium.
RESULTS: HD treatment at blood flow rates of 500 mL/min did not increase plasma free Hb compared to treatments at blood flow rates of 250 mL/min. Frequency of intradialytic BP drops was not different either. By adaptation of the needle size, negative arterial pressure could be kept at a similar level. Urea reduction rates were significantly higher during treatments with higher blood flow rates.
CONCLUSION: Higher blood flow rates can be applied without an increased hemolysis risk provided that needle sizes are adapted accordingly.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18161670

Source DB:  PubMed          Journal:  J Vasc Access        ISSN: 1129-7298            Impact factor:   2.283


  2 in total

Review 1.  Diagnosis, Treatment, and Prevention of Hemodialysis Emergencies.

Authors:  Manish Saha; Michael Allon
Journal:  Clin J Am Soc Nephrol       Date:  2016-11-09       Impact factor: 8.237

2.  Shortened red blood cell age in patients with end-stage renal disease who were receiving haemodialysis: a cross-sectional study.

Authors:  Koichiro Matsumura; Toshika Okumiya; Tetsuro Sugiura; Nobuyuki Takahashi; Yoshihiro Yamamoto; Sanae Kikuchi; Kenichi Fujii; Munemitsu Otagaki; Ichiro Shiojima
Journal:  BMC Nephrol       Date:  2020-09-29       Impact factor: 2.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.